MX2020001547A - Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. - Google Patents

Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Info

Publication number
MX2020001547A
MX2020001547A MX2020001547A MX2020001547A MX2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A
Authority
MX
Mexico
Prior art keywords
fluorobenzofuran
dione
pyrrole
methyl
solid forms
Prior art date
Application number
MX2020001547A
Other languages
English (en)
Inventor
Yamin Zhang
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of MX2020001547A publication Critical patent/MX2020001547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5H-[1,3]dioxolo[4,5-f] indol-7-il)pirrol-2,5-diona, procesos para su preparación, composiciones farmacéuticas de las mismas y usos de las mismas en el tratamiento de enfermedades.
MX2020001547A 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. MX2020001547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
MX2020001547A true MX2020001547A (es) 2020-08-03

Family

ID=63405430

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001547A MX2020001547A (es) 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Country Status (14)

Country Link
US (2) US11136334B2 (es)
EP (1) EP3665176B1 (es)
JP (2) JP7424639B2 (es)
KR (2) KR20240063198A (es)
CN (2) CN117362305A (es)
AU (2) AU2018313259B2 (es)
BR (1) BR112020002892A2 (es)
CA (1) CA3072240A1 (es)
DK (1) DK3665176T3 (es)
FI (1) FI3665176T3 (es)
IL (1) IL272556A (es)
MX (2) MX2020001547A (es)
PT (1) PT3665176T (es)
WO (1) WO2019032958A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018352384B2 (en) 2017-10-16 2023-12-21 Actuate Therapeutics Inc. Solid forms of 3-[5-Fluorobenzofuran-3-yl]-4-[5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl] pyrrole-2,5-dione
CA3100381A1 (en) * 2018-05-17 2019-11-21 Actuate Therapeutics, Inc. Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
WO2024006750A1 (en) * 2022-06-27 2024-01-04 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
NZ600800A (en) 2009-12-23 2014-10-31 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Also Published As

Publication number Publication date
CN111247153B (zh) 2024-04-02
AU2018313259A1 (en) 2020-02-27
AU2023201059A1 (en) 2023-03-23
US11136334B2 (en) 2021-10-05
DK3665176T3 (da) 2024-03-25
IL272556A (en) 2020-03-31
JP7424639B2 (ja) 2024-01-30
CN111247153A (zh) 2020-06-05
MX2023005875A (es) 2023-06-05
KR20200040799A (ko) 2020-04-20
FI3665176T3 (fi) 2024-03-20
WO2019032958A1 (en) 2019-02-14
CA3072240A1 (en) 2019-02-14
JP2020530497A (ja) 2020-10-22
BR112020002892A2 (pt) 2020-08-04
CN117362305A (zh) 2024-01-09
US20220009939A1 (en) 2022-01-13
US20200223861A1 (en) 2020-07-16
AU2018313259B2 (en) 2022-11-24
EP3665176A1 (en) 2020-06-17
KR20240063198A (ko) 2024-05-09
PT3665176T (pt) 2024-03-13
JP2023156372A (ja) 2023-10-24
EP3665176B1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
EP4276114A3 (en) Cd20 binding single domain antibodies
MX2023005875A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
EA201001639A1 (ru) Композиции и способы их получения и применения
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
IN2012DN02624A (es)
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
EA201891612A1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
MY150931A (en) Substituted oxazolidinones and their use
EA201891608A1 (ru) Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EA201891610A1 (ru) Производные 3-(карбоксиэтил)-8-амино-2-оксо-1,3-диазаспиро[4.5]декана
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
EA201891611A1 (ru) Роизводные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.